You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 129 No. 6, June 1972 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Treatment of Vitamin D-Resistant Rickets With 25-Hydroxycholecalciferol

Charles Y. C. Pak, MD; Hector F. DeLuca, PhD; Frederic C. Bartter, MD; Dorothy H. Henneman, MD; Boy Frame, MD; Artemis Simopoulos, MD; Catherine S. Delea

Arch Intern Med. 1972;129(6):894-899.


Abstract

The clinical usefulness of 25-hydroxycholecalciferol (calcifediol, 25-HCC) was determined in three patients with vitamin D-resistant rickets (familial x-linked recessive in two, and familial autosomal dominant in one). Two patients responded favorably to calcifediol (4,000 to 5,000 units/day) by the following criteria: They showed a net retention of calcium and phosphorus. Gastrointestinal absorption of calcium increased. Urinary excretion of phosphorus and the endogenous phosphorus clearance decreased. In one patient (with familial hypophosphatemia) serum phosphorus concentration and alkaline phosphatase activity returned towards normal; urinary total hydroxyproline increased and nondialyzable hydroxyproline decreased. The third patient (with familial hypophosphatemia) responded to calcifediol during the first 16 days of treatment with increases in serum phosphorus concentration and in urinary calcium excretion. However, he became resistant to calcifediol as treatment was continued.



Author Affiliations

Bethesda, Md; Madison, Wis; Bethesda, Md; Raritan, NJ; Detroit; Bethesda, Md

From the Section on Mineral Metabolism, Endocrinology Branch, National Heart and Lung Institute, National Institutes of Health, Bethesda, Md (Drs. Pak, Bartter, Simopoulos, and Miss Delea); Department of Biochemistry, University of Wisconsin, Madison (Dr. DeLuca); Or-; tho Research Laboratories, Raritan, NJ (Dr. Henneman); and Henry Ford Hospital, Detroit (Dr. Frame).


Footnotes

Received for publication March 1, 1971; accepted April 27.

Reprint requests to Section on Mineral Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical School, Dallas (Dr. Pak).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Familial Hypophosphatemic Rickets: A Delineation of Its Subdivisions and Pathogenesis
Walton
CLIN PEDIATR 1976;15:1007-1012.
 

Excretion of Phosphate and Calcium: Physiology of Their Renal Handling and Relation to Clinical Medicine
Massry et al.
Arch Intern Med 1973;131:828-859.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1972 American Medical Association. All Rights Reserved.